New CEO of Renamed Spin-Out Fortovia Therapeutics Will Be ‘Solely US-Focused’
Newly installed Fortovia Therapeutics CEO Peter Melnyk tells Scrip his arrival and the company’s name change from Midatech Pharma US signals a strategic revamp for the privately held spin-out.
You may also be interested in...
Shares in Iovance Biotherapeutics have soared this week amid reports the US clinical-stage biotechnology company is in active M&A talks.
New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.
Trulicity’s broad CV label awarded by the US FDA should aid overall uptake of the GLP-1 class, cushioning the direct impact on Novo Nordisk’s rival, Ozempic, analysts said.